{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dimethyl+sulfoxide",
    "query": {
      "intervention": "dimethyl sulfoxide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dimethyl+sulfoxide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T07:40:30.248Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04709705",
      "title": "DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cardiac Surgery"
      ],
      "interventions": [
        {
          "name": "Human platelets",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellphire Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2021-10-27",
      "completion_date": "2025-05-08",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04709705"
    },
    {
      "nct_id": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Tazemetostat Hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-08-19",
      "completion_date": "2027-03-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 17,
      "location_summary": "Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557956"
    },
    {
      "nct_id": "NCT04201457",
      "title": "A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Glioma (LGG) of Brain With BRAF Aberration",
        "High Grade Glioma (HGG) of the Brain With BRAF Aberration",
        "Low Grade Glioma of Brain With Neurofibromatosis Type 1"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 57,
      "start_date": "2020-01-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201457"
    },
    {
      "nct_id": "NCT02181478",
      "title": "Intra-Osseous Co-Transplant of UCB and hMSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Myelofibrosis",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Lymphoid Malignancies",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "mesenchymal stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-07-22",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181478"
    },
    {
      "nct_id": "NCT02701257",
      "title": "The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus Type 1"
      ],
      "interventions": [
        {
          "name": "iPhone bionic pancreas",
          "type": "DEVICE"
        },
        {
          "name": "iLet bionic pancreas",
          "type": "DEVICE"
        },
        {
          "name": "Xeris Xerisol glucagon",
          "type": "DRUG"
        },
        {
          "name": "Lilly glucagon",
          "type": "DRUG"
        },
        {
          "name": "iLet infusion set",
          "type": "DEVICE"
        },
        {
          "name": "Contact Detach infusion set",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-03",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02701257"
    },
    {
      "nct_id": "NCT03794297",
      "title": "Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Erdheim-Chester Disease"
      ],
      "interventions": [
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-01-04",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03794297"
    },
    {
      "nct_id": "NCT00676507",
      "title": "Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Neoplasm",
        "Carcinoma Non-small Cell Lung Cancer Stage IIIA",
        "Carcinoma Non-small Cell Lung Cancer Stage IIIB",
        "Carcinoma Non-small Cell Lung Cancer Stage IV"
      ],
      "interventions": [
        {
          "name": "Lucanix™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NovaRx Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 532,
      "start_date": "2008-07",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 53,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676507"
    },
    {
      "nct_id": "NCT07321028",
      "title": "Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cellular Injury and Post-Cryogenic Recovery",
        "Cryogenic Cellular Stress",
        "Cold-Induced Cellular Injury",
        "Thermal Injury Response",
        "Post-Thaw Viability Impairment",
        "Osmotic Stress Injury",
        "Biomechanical Injury Modeling (In-Vitro)",
        "Blunt Force Injuries to the Extremities (Cellular Injury Model)",
        "Tissue Damage and Recovery Pathways",
        "Hypothermic Tissue Stress",
        "Cellular Regeneration and Repair"
      ],
      "interventions": [
        {
          "name": "Standard Laboratory Cryopreservation Procedure",
          "type": "OTHER"
        },
        {
          "name": "Enhanced Laboratory Cryopreservation Procedure",
          "type": "OTHER"
        },
        {
          "name": "Normothermic Cell Culture Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Truway Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50,
      "start_date": "2025-12-10",
      "completion_date": "2066-12-10",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07321028"
    },
    {
      "nct_id": "NCT06778434",
      "title": "The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Actinic Keratosis",
        "Imipramine",
        "Photodynamic Therapy"
      ],
      "interventions": [
        {
          "name": "Imipramine",
          "type": "DRUG"
        },
        {
          "name": "Control Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-04-01",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06778434"
    },
    {
      "nct_id": "NCT01336634",
      "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2011-08-05",
      "completion_date": "2021-01-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-22T07:40:30.248Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336634"
    }
  ]
}